Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 31st total of 1,420,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.3% of the company’s shares are short sold.

Athira Pharma Price Performance

NASDAQ:ATHA traded up $0.01 during mid-day trading on Thursday, reaching $0.53. The company’s stock had a trading volume of 463,920 shares, compared to its average volume of 211,201. Athira Pharma has a twelve month low of $0.41 and a twelve month high of $4.30. The company’s fifty day simple moving average is $0.58 and its two-hundred day simple moving average is $1.23. The stock has a market cap of $20.65 million, a P/E ratio of -0.19 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. Sell-side analysts expect that Athira Pharma will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Athira Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATHA. American Century Companies Inc. lifted its position in shares of Athira Pharma by 9.4% during the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Athira Pharma by 3.5% in the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares during the period. XTX Topco Ltd acquired a new stake in shares of Athira Pharma in the second quarter valued at approximately $60,000. Invst LLC acquired a new position in Athira Pharma during the 2nd quarter worth $68,000. Finally, Dimensional Fund Advisors LP grew its position in Athira Pharma by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after buying an additional 111,759 shares in the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.